PURPOSE: To investigate the expression of SRHC and the role of SRHC in the pathogenesis of hepatocellular carcinoma (HCC). METHODS: We analyzed HCC samples and matched non-tumor liver tissues (controls) collected from 81 patients who underwent hepatectomy in Shanghai, China. The expression levels of SRHC were determined by quantitative reverse-transcription polymerase chain reaction. Statistical analyses were used to associate the levels of SRHC with tumor features and patient outcomes. RESULTS: We found that a lower SRHC expression level was significantly more frequent in tissues with a high serum a-fetoprotein level (positive, >20 µg/L, P = 0.004) and a low degree of differentiated tumors (poorly differentiated, P = 0.017). Furthermore, we found that the promoter region of SRHC contains a CpG-rich island and that SRHC is down-regulated in tumors by DNA methylation. CONCLUSION: Here, we identified a new long noncoding RNA designated as SRHC that is capable of inhibiting cancer proliferation and is down-regulated in tumors at least partly by DNA methylation.
PURPOSE: To investigate the expression of SRHC and the role of SRHC in the pathogenesis of hepatocellular carcinoma (HCC). METHODS: We analyzed HCC samples and matched non-tumor liver tissues (controls) collected from 81 patients who underwent hepatectomy in Shanghai, China. The expression levels of SRHC were determined by quantitative reverse-transcription polymerase chain reaction. Statistical analyses were used to associate the levels of SRHC with tumor features and patient outcomes. RESULTS: We found that a lower SRHC expression level was significantly more frequent in tissues with a high serum a-fetoprotein level (positive, >20 µg/L, P = 0.004) and a low degree of differentiated tumors (poorly differentiated, P = 0.017). Furthermore, we found that the promoter region of SRHC contains a CpG-rich island and that SRHC is down-regulated in tumors by DNA methylation. CONCLUSION: Here, we identified a new long noncoding RNA designated as SRHC that is capable of inhibiting cancer proliferation and is down-regulated in tumors at least partly by DNA methylation.
Authors: Yaomin Xu; Bo Hu; Ae-Jin Choi; Banu Gopalan; Byron H Lee; Matthew F Kalady; James M Church; Angela H Ting Journal: Genome Res Date: 2011-10-11 Impact factor: 9.043
Authors: John R Prensner; Matthew K Iyer; Anirban Sahu; Irfan A Asangani; Qi Cao; Lalit Patel; Ismael A Vergara; Elai Davicioni; Nicholas Erho; Mercedeh Ghadessi; Robert B Jenkins; Timothy J Triche; Rohit Malik; Rachel Bedenis; Natalie McGregor; Teng Ma; Wei Chen; Sumin Han; Xiaojun Jing; Xuhong Cao; Xiaoju Wang; Benjamin Chandler; Wei Yan; Javed Siddiqui; Lakshmi P Kunju; Saravana M Dhanasekaran; Kenneth J Pienta; Felix Y Feng; Arul M Chinnaiyan Journal: Nat Genet Date: 2013-09-29 Impact factor: 38.330